ESMO 2023
Research and breaking news from the European Society for Medical Oncology Congress, taking place in Madrid, Spain, October 20-24, 2023.
A study aimed to evaluate the feasibility of ddPCR to detect specific driver gene mutations in patients with resected NSCLC.
Participating patients received PERT at baseline or within 3 months of receiving first-line treatment.
Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.
Perioperative immunotherapy both before and after surgery significantly improves EFS in operable early-stage NSCLC.
Immune evasion alterations impact the duration of response to checkpoint inhibitors in patients with metastatic NSCLC.
Neoadjuvant pembrolizumab in combination with chemotherapy followed by resection and adjuvant pembro improves OS in NSCLC.
Dostarlimab and chemotherapy combo demonstrates robust safety and efficacy in treating metastatic nonsquamous NSCLC.
Advertisement
Advertisement
